2024
Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs?
Woodard G, Jablons D. Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs? Journal Of Thoracic Oncology 2024, 19: 1135-1137. PMID: 39111999, DOI: 10.1016/j.jtho.2024.06.007.Peer-Reviewed Original ResearchShould the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
Woodard G, Dacic S. Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors? Journal Of Thoracic Oncology 2024, 19: 663-665. PMID: 38719420, DOI: 10.1016/j.jtho.2024.01.004.Peer-Reviewed Original Research
2023
Increased Lymphocyte Infiltration in NSCLC Neoadjuvant Chemo-Immunotherapy Non-responders: A Biomarker of T-Cell Dysfunction and Prognosis?
Woodard G, Cho C, Chen L. Increased Lymphocyte Infiltration in NSCLC Neoadjuvant Chemo-Immunotherapy Non-responders: A Biomarker of T-Cell Dysfunction and Prognosis? Annals Of Surgical Oncology 2023, 31: 25-27. PMID: 37899411, DOI: 10.1245/s10434-023-14388-1.Peer-Reviewed Original ResearchComparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas
Woodard G, Ding V, Cho C, Brand N, Kratz J, Jones K, Jablons D. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas. Lung Cancer 2023, 180: 107211. PMID: 37121213, PMCID: PMC10900430, DOI: 10.1016/j.lungcan.2023.107211.Peer-Reviewed Original ResearchConceptsInvasive portionDriver mutationsSolid adenocarcinomaLung cancer driver mutationsNext-generation sequencingWarrants further studyLobar resectionClinical characteristicsSurgical databaseAsian patientsInvasive cancerPoor prognosisLung cancerLung lesionsInvasive componentInvasive solid tumorsNormal lungLepidicStage IPromising biomarkerSolid tumorsCancer developmentSame time periodGenes SPP1Gene expressionThe Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer
Grant M, Woodard G, Goldberg S. The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 513-531. PMID: 37024389, DOI: 10.1016/j.hoc.2023.02.003.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsMutationProtein-Tyrosine KinasesProto-Oncogene ProteinsConceptsNon-small cell lung cancerCell lung cancerLung cancerMetastatic non-small cell lung cancerResectable non-small cell lung cancerImmuno-oncology agentsHistologic classification systemUnited States FoodResectable tumorsSystemic therapyDriver alterationsDrug AdministrationStates FoodSystemic managementPatientsTherapyCancerEvolving roleClassification systemNTRKHER2TumorsKRASEGFRBRAF
2022
Thoracic CT follow-up after non-small-cell lung cancer resection
Woodard G, Boffa D, Blasberg J. Thoracic CT follow-up after non-small-cell lung cancer resection. The Lancet Oncology 2022, 23: e484. PMID: 36328013, DOI: 10.1016/s1470-2045(22)00618-0.Commentaries, Editorials and LettersCould Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?
Woodard GA, Cho C, Chen L. Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response? Journal Of Thoracic Oncology 2022, 17: 592-595. PMID: 35465963, DOI: 10.1016/j.jtho.2022.03.009.Peer-Reviewed Original Research
2021
Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay
Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay. Future Oncology 2021, 17: 4785-4795. PMID: 34435876, PMCID: PMC9039775, DOI: 10.2217/fon-2021-0517.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinogenesisCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantClinical Decision-MakingDatasets as TopicDisease-Free SurvivalGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLung NeoplasmsMolecular Diagnostic TechniquesNeoplasm Recurrence, LocalNeoplasm StagingPneumonectomyProspective StudiesReal-Time Polymerase Chain ReactionRisk AssessmentConceptsCell lung cancerUndetectable metastasesLung cancerCell lung cancer patientsDisease-free survivalAdjuvant chemotherapy decisionsTime of surgeryLung cancer patientsSurgical resectionComplete resectionProspective studyCancer patientsChemotherapy decisionsResectionMolecular assaysPatientsPredictive benefitMetastasisCancerMortalityQuantitative PCRExpression profilesEarly stagesAssaysSurgeryMolecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy
Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clinical Lung Cancer 2021, 22: 587-595. PMID: 34544620, DOI: 10.1016/j.cllc.2021.08.008.Peer-Reviewed Original ResearchConceptsMolecular risk stratificationAdjuvant chemotherapyDisease-free survivalEGFR mutation statusAdjuvant interventionRisk stratificationEGFR patientsNSCLC patientsEGFR statusMutation statusSmall cell lung cancer patientsNon-squamous NSCLC patientsCell lung cancer patientsStage IA NSCLCStage IB patientsThird-generation TKIsEarly-stage NSCLCNon-Squamous NonLung cancer patientsEarly-stage cohortIB patientsProspective studyResidual diseaseCancer patientsEGFR mutationsRole of adjuvant therapy in T1-2N0 resected non–small cell lung cancer
Woodard GA, Li A, Boffa DJ. Role of adjuvant therapy in T1-2N0 resected non–small cell lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2021, 163: 1685-1692. PMID: 34334172, DOI: 10.1016/j.jtcvs.2021.05.053.Peer-Reviewed Original Research
2020
Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma
Yang YW, Marrufo A, Chase J, Woodard GA, Jablons DM, Lemjabbar-Alaoui H. Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma. Experimental Lung Research 2020, 47: 9-25. PMID: 33107354, DOI: 10.1080/01902148.2020.1836691.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisCell Line, TumorHumansImidazolesLung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsPyridazinesConceptsMalignant pleural mesotheliomaPonatinib treatmentPleural mesotheliomaMPM linesTherapeutic approachesPotential therapeutic approachExpression levelsNew therapeutic strategiesHuman MPM cellsMPM therapyPSTAT5 levelsWestern blot analysisMPM patientsMPM treatmentDeadly malignancyLevels of γH2AXPotential utilityTherapeutic strategiesTumor growthMPM cellsPathway inhibitionTumor modelPonatinibActivation of AblTumor samples
2019
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e1917062. PMID: 31808928, PMCID: PMC6902768, DOI: 10.1001/jamanetworkopen.2019.17062.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTNM staging systemDisease-free survivalHigh-risk patientsCell lung cancerStaging systemEighth editionSurgical resectionLung cancerConventional TNMPrognostic classifierNonsquamous non-small cell lung cancerQuaternary care medical centerDisease-free survival ratesHigh molecular riskSurvival 3 yearsEarly-stage diseaseConventional TNM stagingCritical unmet needCohort studyPrimary outcomeConsecutive seriesTNM stagingMolecular riskConcordance indexIncorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging
Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging. Journal Of Thoracic Oncology 2019, 14: 1223-1232. PMID: 30959120, DOI: 10.1016/j.jtho.2019.03.015.Peer-Reviewed Original Research
2018
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation
Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clinical Lung Cancer 2018, 20: e137-e141. PMID: 30553716, DOI: 10.1016/j.cllc.2018.11.003.Peer-Reviewed Original ResearchScientific Advances and New Frontiers in Mesothelioma Therapeutics
Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal Of Thoracic Oncology 2018, 13: 1269-1283. PMID: 29966799, PMCID: PMC6643278, DOI: 10.1016/j.jtho.2018.06.011.Peer-Reviewed Original Research
2017
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer
Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2017, 19: 58-64. PMID: 28645632, DOI: 10.1016/j.cllc.2017.05.015.Peer-Reviewed Original ResearchConceptsHigh-risk patientsDisease-free survivalLow-risk patientsAdjuvant chemotherapyNational Comprehensive Cancer Network guidelinesCell lung cancer patientsMolecular profilingEarly-stage NSCLCHigh-risk criteriaLog-rank analysisCell lung cancerHigh-risk designationLung cancer patientsKaplan-Meyer estimatesAdjuvant treatmentNonsquamous NSCLCOccult metastasesStage IAStage NSCLCAdjuvant interventionClinicopathologic characteristicsComplete resectionConsecutive patientsDisease recurrenceNCCN criteria
2016
Lung Cancer Staging and Prognosis
Woodard GA, Jones KD, Jablons DM. Lung Cancer Staging and Prognosis. Cancer Treatment And Research 2016, 170: 47-75. PMID: 27535389, DOI: 10.1007/978-3-319-40389-2_3.Peer-Reviewed Original ResearchConceptsTNM stageLung Cancer Lung Cancer Staging ProjectCancer TNM staging systemLung Cancer Staging ProjectSurvival estimatesIndividualized survival estimatesNew immunotherapy drugsStage IA diseaseStage IV diseaseImportant prognostic factorTNM staging systemPoor prognostic indicatorMolecular prognostic markersSignificant survival differenceTumor histologic gradeLung cancer stagingMolecular tumor profilingGenetic tumor analysisIA diseaseTNM groupingsOverall survivalPerformance statusMolecular prognosticationPD-L1Prognostic factorsGli promotes epithelial-mesenchymal transition in human lung adenocarcinomas
Li H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas. Oncotarget 2016, 5: 80415-80425. PMID: 27533453, PMCID: PMC5348330, DOI: 10.18632/oncotarget.11246.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAdenocarcinomaAdenocarcinoma of LungAnimalsAntigens, CDAntineoplastic AgentsCadherinsCell MovementEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHedgehog ProteinsHumansLung NeoplasmsMaleMice, NudeMiddle AgedNeoplasm InvasivenessSignal TransductionSmoothened ReceptorTime FactorsTumor BurdenXenograft Model Antitumor AssaysZinc Finger Protein GLI1ConceptsEpithelial-mesenchymal transitionLung adenocarcinomaE-cadherin expressionTumor growthLung adenocarcinoma metastasisPotential therapeutic targetInhibition of GLICell migrationAdenocarcinoma metastasisLung cancerInvasion/metastasisTumor invasion/metastasisIndependent cohortGLI inhibitorsSmall molecule inhibitorsTherapeutic targetAdenocarcinomaHuman lungTherapeutic agentsMetastasisCell invasionWound healingCommon typeRole of GliMolecule inhibitorsConsensus Report of the 2015 Weinman International Conference on Mesothelioma
Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. Journal Of Thoracic Oncology 2016, 11: 1246-1262. PMID: 27453164, PMCID: PMC5551435, DOI: 10.1016/j.jtho.2016.04.028.Peer-Reviewed Original ResearchConceptsMalignant mesotheliomaOverall survivalHigh mobility group box 1Mobility group box 1Development of MMIncidence of MMGroup box 1Novel therapeutic approachesNational Cancer InstitutePublic health authoritiesU.S. National Cancer InstitutePreventable malignancyStandard chemotherapyCancer CenterBlood biomarkersLung cancerMineral fibersClinical trialsCurrent treatmentOccupational exposureProtein 1 mutationConsensus reportTherapeutic approachesGermline BRCA1Clinical OncologySignificance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics
Yang D, Woodard G, Zhou C, Wang X, Liu Z, Ye Z, Li K. Significance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics. Thoracic Cancer 2016, 7: 535-542. PMID: 27766777, PMCID: PMC5130210, DOI: 10.1111/1759-7714.12363.Peer-Reviewed Original ResearchConceptsProgression-free survivalResponse Evaluation CriteriaTumor cavitationPrognostic informationTreatment responseTumor responseTumor densitySignificant differencesPrediction of PFSRadiographic treatment responseAdditional prognostic informationUseful prognostic signCertain radiographic signsPrognostic signTumor diameterLung cancerShort-axis sizeRadiographic signsTumor assessmentPatientsSolid tumorsTumor changesRECIST1.1Imaging characteristicsPFS